| AdventHealth Research Institute

NCT05563220

STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)

This study is currently enrolling.

This research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer: alpelisib, everolimus, pal ...

NCT05671510

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

This study is currently enrolling.

The main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care chemotherapy drug, docetaxel. ...

NCT05165433

NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)

This study is currently enrolling.

The purpose of this research study is to test how safe and well-tolerated treatment with the study drug is in combination with pembrolizumab and to find out more about the side-effects. The study aims to determine the following ...

NCT05219617

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CARISBAMATE (YKP509) AS ADJUNCTIVE TREATMENT FOR SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN CHILDREN AND ADULTS,
WITH OPTIONALOPEN-LABEL EXTENSION

This study is currently enrolling.

Participants will be asked to join this study because they have Lennox-Gastaut Syndrome (LGS), a rare type of epilepsy that results in abnormal brain activity and seizures. It usually starts at an early age and causes seizures ...

NCT05869669

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

This study is currently enrolling.

The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, the aim of this study is to find out if you e ...

NCT05685303

ALLAY-HF: Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure

This study is currently enrolling.

To evaluate the safety and efficacy of the Alleviant ALV1 System in patients with chronic heart failure (HF) and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), who remain symptomatic despite a ...

NCT05198674

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)

This study is currently enrolling.

The purpose of this study is to study renal denervation with the Symplicity Spyral Renal Denervation system in patients with varying severity of uncontrolled high blood pressure and associated conditions. The focus of this stud ...

NCT04795713

MT-6402-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

To evaluate the safety and tolerability of MT-6402 in subjects with advanced cancer (solid tumors) and to estimate the maximum tolerated dose (MTD). To evaluate efficacy of MT-6402 in subjects with advanced cancer by using obje ...

NCT05284747

20190184: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

This study is currently enrolling.

This study is being done to learn whether regular healthcare, combined with early treatment with a cholesterol lowering drug called evolocumab (Repatha) reduces heart attack, stroke, procedures to improve blood flow and death, ...

Subscribe to

STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)

PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors

NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CARISBAMATE (YKP509) AS ADJUNCTIVE TREATMENT FOR SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN CHILDREN AND ADULTS,
WITH OPTIONALOPEN-LABEL EXTENSION

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

ALLAY-HF: Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure

The SPYRAL AFFIRM Global Clinical Study of Renal Denervation with the Symplicity Spyral Renal Denervation System in Subjects with Uncontrolled Hypertension (SPYRAL AFFIRM)

MT-6402-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

20190184: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Explore

Institutes